Evidence map›Paper›PMID 33094031›Full record

ArticleCurrent pathobiology reports2019

Next Generation Techniques for Determination of Protein-Protein Interactions: Beyond the Crystal Structure.

Rachel Carter, Alessandra Luchini, Lance Liotta, Amanda Haymond

Abstract read
In one paragraph

Article in Current pathobiology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Molecular basis for protein-protein interactions.Beilstein journal of organic chemistry · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rachel CarterCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA.ORCID 0000-0003-4858-5936
Alessandra LuchiniCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA.ORCID 0000-0003-1599-0214
Lance LiottaCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA.ORCID 0000-0001-5155-7907
Amanda HaymondCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA.ORCID 0000-0002-9553-275X

Funding

Probes to target the 3-way hotspot of IL1RacP to abolish aberrant interleukin inflammationR01AR068436 · NIAMS · GEORGE MASON UNIVERSITY · PI LIOTTA, LANCE ALLEN · 2015 to 2017
$1.7M
Protein painting identifies therapeutic targets at protein-protein interfacesR33CA206937 · NCI · GEORGE MASON UNIVERSITY · PI LIOTTA, LANCE ALLEN · 2016 to 2018
$1.2M
NCI NIH HHS R33 CA206937NIAMS NIH HHS R01 AR068436
6 · The paper itself

Abstract

purpose of reviewWe discuss recent advancements in structural biology methods for investigating sites of protein-protein interactions. We will inform readers outside the field of structural biology about techniques beyond crystallography, and how these different technologies can be utilized for drug development. RECENT

findingsAdvancements in cryo-electron microscopy (cryoEM) and micro-electron diffraction (microED) may change how we view atomic resolution structural biology, such that well-ordered macrocrystals of protein complexes are not required for interface identification. However, some drug discovery applications, such as lead peptide compound generation, may not require atomic resolution; mass spectrometry techniques can provide an expedited path to generation of lead compounds. New crosslinking compounds, more user-friendly data analysis, and novel protocols such as protein painting can advance drug discovery programs, even in the absence of atomic resolution structural data. Finally, artificial intelligence and machine learning methods, while never truly replacing experimental methods, may provide rational ways to stratify potential druggable regions identified with mass spectrometry into higher and lower priority candidates. SUMMARY: Electron diffraction of nanocrystals combines the benefits of both x-ray diffraction and cryoEM, and may prove to be the next generation of atomic resolution protein-protein interface identification. However, in situations such as peptide drug discovery, mass spectrometry techniques supported by advancements in computational methods will likely prove sufficient to support drug discovery efforts. In addition, these methods can be significantly faster than any crystallographic or cryoEM methods for identification of interacting regions.

Indexed as

computational modelingcrystallographyhotspotsmass spectrometryprotein-protein interactionsStructural biology

Identifiers

PMID33094031
PMCPMC7577580

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.